---
title: "NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263283008.md"
description: "NLS Pharmaceutics and Kadimastem have announced the continuation of the ITOL-102 diabetes program following their merger into NewCelX Ltd. This program focuses on developing a stem-cell-derived therapy for Type 1 Diabetes, aiming to eliminate the need for lifelong immunosuppression. The initiative is supported by the BIRD Foundation and represents NLS's strategic move into regenerative medicine. NLS Pharmaceutics specializes in therapies for CNS disorders, while Kadimastem develops cell products for neurodegenerative diseases and diabetes. Current market cap is $4.46M with a trading volume of 676,799."
datetime: "2025-10-29T11:57:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263283008.md)
  - [en](https://longbridge.com/en/news/263283008.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263283008.md)
---

# NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger

NLS Pharmaceutics ( (NLSP) ) has shared an update.

On October 29, 2025, NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the continuation of the ITOL-102 cell therapy program for Type 1 Diabetes under the newly merged entity, NewCelX Ltd. The program, originally supported by a grant from the BIRD Foundation, aims to develop a stem-cell-derived pancreatic islet cell therapy capable of curing Type 1 Diabetes without lifelong immunosuppression. This merger and continued support from the BIRD Foundation highlight NLS’s strategic expansion into regenerative and metabolic medicine, leveraging Kadimastem’s advanced stem-cell platform.

**More about NLS Pharmaceutics**

NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and related indications. Kadimastem Ltd. is a clinical-stage cell therapy company developing allogeneic, ‘off-the-shelf’ cell products for neurodegenerative diseases and diabetes.

**Average Trading Volume:** 676,799

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $4.46M

### Related Stocks

- [NLSP.US](https://longbridge.com/en/quote/NLSP.US.md)
- [NCEL.US](https://longbridge.com/en/quote/NCEL.US.md)

## Related News & Research

- [EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug](https://longbridge.com/en/news/284765384.md)
- [BUZZ-NewcelX rises after raising funds at premium to boost diabetes program](https://longbridge.com/en/news/281358909.md)
- [NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing | NCEL Stock News](https://longbridge.com/en/news/281357100.md)
- [NewcelX and Eledon partner for NCEL-101 programme](https://longbridge.com/en/news/278530365.md)
- [07:00 ETNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes](https://longbridge.com/en/news/278377867.md)